Document is current
Any future updates will be listed below
-
Authors
de Jong, Rineke
Zhou, Fan
Andersen, Tor Kristian
Stockhofe-Zurwieden, Norbert
Cox, Rebecca Jane
Bogen, Bjarne
Grodeland, Gunnveig
-
Funding
Funding for this research was provided by:
Stiftelsen K.G. Jebsen
Helse Sør-Øst RHF (2017066)
TRANSVAC H2020
Norges Forskningsråd (287872)
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 2 December 2025
First Online: 24 December 2025
Competing interests
: GG and BB are inventors on a patent on the HLAII-specific targeting moiety used herein. BB is also an inventor on several Vaccibody-related patents (basis-patent, MIP-1α), and is a co-founder of the Nykode company and holds shares in the company. RJ, FZ, TKA, NSZ and RJC declare no competing interests.
